Effect of Vitamin d Deficiency in Chronic Rhinosinusitis With Nasal Polyposis
NCT ID: NCT04529668
Last Updated: 2020-08-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
50 participants
INTERVENTIONAL
2015-10-01
2020-10-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. To determine if chronic rhinosinusitis with nasal polyps' (CRSwNP) populations are vitamin D deficient.
2. To determine the possible anti-inflammatory effect of vitamin D supplementation (clinically \& histologically). \& investigate its relation to immunohistochemical tissue expression of basic fibroblast growth factor
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Study groups:
Fifty patients with the clinical diagnosis of chronic rhinosinusitis with nasal Polyposis (CRSwNP) resistant to medical treatment at Otorhinolaryngology outpatient clinic, Ain Shams University hospitals. Group I : twenty five patients will receive vitamin D supplementation, while group II won't receive vitamin D supplementation.
Inclusion criteria:
Patients (18-60) years of age with clinical diagnosis of chronic rhinosinusitis with nasal Polyposis (CRSwNP) resistant to medical treatment at Otorhinolaryngology outpatient clinic, Ain Shams University hospital.
Both groups (I \& II) will be subjected to venous blood sampling and 25(OH) vitamin D level measurement \& will be subjected to:
1. Careful history taking.
2. Complete ENT examination and endoscopic evaluation of the nose.
3. CT scan paranasal sinuses coronal and axial view to evaluate the affected sinuses.
4. Vitamin D3 serum level (before Vitamin D3 supplementation).
5. Biopsy from nasal polyps \& immunohistochemical assessment (before Vitamin D3 supplementation).
6. Vitamin D3 supplementation 50000 IU/weekly for 6 weeks.
7. Vitamin D3 serum level (after Vitamin D3 supplementation).
8. Biopsy from nasal polyps \& immunohistochemical assessment (after Vitamin D3 supplementation).
Exclusion criteria:
* Pregnant and lactating females.
* Patients taking multivitamins containing vitamin D for at least six months.
* Immune deficiency or suppression.
* Ciliary motility disorders.
* Wegner's granulomatosis and other granulomatous diseases.
* Sino-nasal malignancy.
1. History:
1. Personal history: name, age, sex, occupation and environment (smoking, exposure to irritants).
2. Complaint and history of present illness: analysis of the patient's chief complaints with special emphasis on CRS symptoms.
3. Medical history: Previous medical treatment for CRS (antibiotics, topical and systemic corticosteroids, etc...) or for any other disease (allergy, hypertension, asthma, GERD, etc...) including questions about the dose and duration of treatment and the achieved results. It included also past history of surgery.
4. Family history: History of allergy, asthma, polyposis, migraine, genetic diseases, etc….
2. Examination:
1. General examination: it will be done for all patients as a routine.
2. Local examination (complete ENT examination): Oral, laryngeal and ear examination will be done to exclude other ENT disease and then careful nasal examination will be done.
3. Endoscopic examination: Diagnostic nasal endoscopy will be done for all patients.
3. Investigations:
A- CT scans will be done (in coronal, axial planes) for all patients with chronic rhinosinusitis with nasal Polyposis (CRSwNP).
B- 25-OH Vitamin D serum level: (before \& after vitamin D supplementation)
4. Biopsy from nasal polyps :
Tissue samples will be taken from the nasal polyps of all patients with chronic rhinosinusitis with nasal Polyposis (CRSwNP) at the start of the study (before VD therapy) under local anesthesia at the outpatient clinic for histological (epithelium, basal lamina, lamina propria, cells, blood vessels) \& immunohistochemical (basic fibroblast growth factors) examination.
5. Vitamin D3 supplementation:
Vitamin D3 (cholecalciferol) will be given to the study group Ia orally 50000 IU weekly for 6 weeks. In addition to local nasal steroids \& saline nasal wash. All patients will be monitored by serum calcium level. While group Ib will not be given vitamin D supplementation.
6. Biopsy from nasal polyps :
Tissue samples will be taken from the nasal polyps of all patients with chronic rhinosinusitis with nasal Polyposis (CRSwNP) after vitamin D supplementation for immunohistochemical assessment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
group I
twenty-five patients with the clinical diagnosis of chronic rhinosinusitis with nasal Polyposis will receive vitamin D supplementation
vitamin D supplementation
vitamin D supplementation
group II
twenty-five patients with the clinical diagnosis of chronic rhinosinusitis with nasal Polyposis will NOT receive vitamin D supplementation
usual therapy for nasal polyposis
steroids ( systemic and local )
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
vitamin D supplementation
vitamin D supplementation
usual therapy for nasal polyposis
steroids ( systemic and local )
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients taking multivitamins containing vitamin D for at least six months.
* Immune deficiency or suppression.
* Ciliary motility disorders.
* Wegner's granulomatosis and other granulomatous diseases.
* Sino-nasal malignancy.
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ain Shams University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mohammad Salah Mohammad Mahmoud
Doctor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ain shams Univesrity
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Fatma S Ebeid, MD
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, Cohen N, Cervin A, Douglas R, Gevaert P, Georgalas C, Goossens H, Harvey R, Hellings P, Hopkins C, Jones N, Joos G, Kalogjera L, Kern B, Kowalski M, Price D, Riechelmann H, Schlosser R, Senior B, Thomas M, Toskala E, Voegels R, Wang de Y, Wormald PJ. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology. 2012 Mar;50(1):1-12. doi: 10.4193/Rhino12.000.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FMASUMD241/2015
Identifier Type: -
Identifier Source: org_study_id